On Tuesday September 1, 2019 Novartis and Microsoft announced a multiyear alliance which will leverage data & Artificial Intelligence (AI) to transform how medicines are discovered, developed and commercialized. Novartis is also establishing an AI Innovation Lab to empower associates to use AI across our business.

Health experts from around the world met November 29 to discuss ways to tackle an emerging crisis.

Novartis reaffirms commitment to fighting malaria and recognizes the dedication of our people and partners.

Fourteen weeks. That’s how many weeks all new Novartis parents will get as minimum paid parental leave, regardless of gender, rolling out from July 1, 2019.

Blood diseases place a huge burden on individual patients, their families and on wider society. Yet advances in hematology treatment give so much cause for hope. It’s our responsibility to turn that hope into reality. Hear from five bold advocates who inspire us.

Novartis and other industry leaders call for action to address antimicrobial resistance, one of the world’s most serious public health challenges

Volunteerism and giving back to communities where we live and work are more than just tradition; they’re core values.

Novartis is one of 73 companies included in the 2017 Water A List by CDP, the nonprofit global environmental disclosure platform.

RAND Corporation and the Moran Company issued reports discussing the cost savings associated with biosimilars.

Leprosy is an ancient disease that currently infects more than 200 000 people each year. For more than three decades, Novartis and the Novartis Foundation has been working to reduce the incidence of leprosy, and the Novartis Foundation recently helped establish the Global Partnership for Zero Leprosy in an effort to eliminate the disease.